Katie Kosko

DocwireNews

Imlunestrant plus abemaciclib showed consistent benefit over imlunestrant alone in patients with estrogen receptor-positive (ER-positive), HER2-negative advanced breast cancer regardless of biomarker status or prior CDK4/6 inhibitor treatment (CDK4/6i), according to a subgroup analysis from the EMBER-3 clinical trial.
The combination significantly improved progression-free survival (PFS) over imlunestrant across key clinicogenomic subgroups. Findings were presented by Cristina Saura Manich, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, during the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held in Munich, Germany.
“EMBER-3 is the first phase 3 trial to show benefit of an oral selective estrogen receptor degrader (SERD) plus CDK4/6i after disease progression on prior CDK4/6i,” Saura said.
The phase 3, open-label trial enrolled 874 patients with ER-positive, HER2-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, given alone or with a CDK4/6 inhibitor.
Patients were randomly assigned 1:1:1 to receive imlunestrant, standard of care (SOC) endocrine monotherapy, or imlunestrant plus abemaciclib.
The study’s primary end points were investigator-assessed PFS for imlunestrant compared with SOC in patients with ESR1 mutations, imlunestrant versus SOC endocrine monotherapy in all patients, and imlunestrant plus abemaciclib versus imlunestrant alone in all patients. The subgroup analysis presented at ESMO examined PFS for the combination compared with monotherapy among patients pretreated with CDK4/6i.
Of the 426 patients included in the analysis, the majority (65%) received prior CDK4/6i therapy with palbociclib being the most used. Prior to trial enrollment, 70% of pretreated patients were on CDKJ4/6i therapy for at least 12 months.
More than half (56%) of patients had visceral metastases, 37% had ESR1 mutations, and 40% had PI3K-pathway mutations, including PIK3CA, AKT1, and PTEN.
Results of the study showed a PFS benefit from the combination therapy compared with single agent imlunestrant. The median PFS was 9.1 months versus 3.7 months, respectively. Moreover, this effect was consistent across multiple clinicogenomic subgroups, including ESR1 and PI3K-pathway mutations. The survival benefit was observed regardless of the duration or type of CDK4/6i received by patients during previous treatment, Dr. Saura said.
Previous research published in the New England Journal of Medicine showed a PFS of 9.4 months among patients treated with imlunestrant plus abemaciclib versus 5.5 months with imlunestrant alone.
<h3>References:</h3>
<ol>
<li>Abstract 297O. ESMO Breast Cancer Annual Congress. <a href="https://clin.larvol.com/abstract-detail/ESMO-BC%202025/75278122" target="_blank" rel="noopener">https://clin.larvol.com/abstract-detail/ESMO-BC%202025/75278122</a></li>
<li>Jhaveri KL, et al. N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi:10.1056/NEJMoa2410858.</li>
</ol>

Imlunestrant plus abemaciclib showed consistent benefit over imlunestrant alone in patients with estrogen receptor-positive (ER-positive), HER2-negative advanced breast cancer regardless of biomarker status or prior CDK4/6 inhibitor treatment (CDK4/6i), according to a subgroup analysis from the EMBER-3 clinical trial.The combination significantly improved progression-free survival (PFS) over imlunestrant across key clinicogenomic subgroups. Findings were presented by Cristina Saura Manich, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, during the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held in Munich, Germany.“EMBER-3 is the first phase 3 trial to show benefit of an oral selective estrogen receptor degrader (SERD) plus CDK4/6i after disease progression on prior CDK4/6i,” Saura said.The phase 3, open-label trial enrolled 874 patients with ER-positive, HER2-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, given alone or with a CDK4/6 inhibitor.Patients were randomly assigned 1:1:1 to receive imlunestrant, standard of care (SOC) endocrine monotherapy, or imlunestrant plus abemaciclib.The study’s primary end points were investigator-assessed PFS for imlunestrant compared with SOC in patients with ESR1 mutations, imlunestrant versus SOC endocrine monotherapy in all patients, and imlunestrant plus abemaciclib versus imlunestrant alone in all patients. The subgroup analysis presented at ESMO examined PFS for the combination compared with monotherapy among patients pretreated with CDK4/6i.Of the 426 patients included in the analysis, the majority (65%) received prior CDK4/6i therapy with palbociclib being the most used. Prior to trial enrollment, 70% of pretreated patients were on CDKJ4/6i therapy for at least 12 months.More than half (56%) of patients had visceral metastases, 37% had ESR1 mutations, and 40% had PI3K-pathway mutations, including PIK3CA, AKT1, and PTEN.Results of the study showed a PFS benefit from the combination therapy compared with single agent imlunestrant. The median PFS was 9.1 months versus 3.7 months, respectively. Moreover, this effect was consistent across multiple clinicogenomic subgroups, including ESR1 and PI3K-pathway mutations. The survival benefit was observed regardless of the duration or type of CDK4/6i received by patients during previous treatment, Dr. Saura said.Previous research published in the New England Journal of Medicine showed a PFS of 9.4 months among patients treated with imlunestrant plus abemaciclib versus 5.5 months with imlunestrant alone.<h3>References:</h3><ol>
<li>Abstract 297O. ESMO Breast Cancer Annual Congress. <a href="https://clin.larvol.com/abstract-detail/ESMO-BC%202025/75278122" target="_blank" rel="noopener">https://clin.larvol.com/abstract-detail/ESMO-BC%202025/75278122</a></li>
<li>Jhaveri KL, et al. N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi:10.1056/NEJMoa2410858.</li>
</ol>

Lauren Dembeck, PhD

Digital Inhaler Metrics May Predict Impending Acute COPD Exacerbations

Pulmonology

Mithu Maheswaranathan, MD

Ordering of HLA-B27 in Clinical Practice

Rheumatology

Anne Marie Morse, DO

Rob Dillard

AI in Sleep Medicine: Augmenting Care, Not Replacing It

Sleep Disorders

Latest News

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Imlunestrant plus abemaciclib improved PFS across subgroups in ER+/HER2- breast cancer, per EMBER-3 data. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe